HEADER TRANSFERASE 01-APR-20 6YI8 TITLE HUMAN FGFR4 KINASE DOMAIN (447-753) IN COMPLEX WITH ROBLITINIB COMPND MOL_ID: 1; COMPND 2 MOLECULE: FIBROBLAST GROWTH FACTOR RECEPTOR 4; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: FGFR-4; COMPND 5 EC: 2.7.10.1 SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606 KEYWDS TYROSINE KINASE INHIBITOR, COVALENT REVERSIBLE INHIBITOR, FGFR4, KEYWDS 2 ROBLITINIB, TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR N.OSTERMANN REVDAT 3 24-JAN-24 6YI8 1 HETSYN REVDAT 2 25-NOV-20 6YI8 1 JRNL REVDAT 1 30-SEP-20 6YI8 0 JRNL AUTH R.A.FAIRHURST,T.KNOEPFEL,N.BUSCHMANN,C.LEBLANC,R.MAH, JRNL AUTH 2 M.TODOROV,P.NIMSGERN,S.RIPOCHE,M.NIKLAUS,N.WARIN,V.H.LUU, JRNL AUTH 3 M.MADOERIN,J.WIRTH,D.GRAUS-PORTA,A.WEISS,M.KIFFE,M.WARTMANN, JRNL AUTH 4 J.KINYAMU-AKUNDA,D.STERKER,C.STAMM,F.ADLER,A.BUHLES, JRNL AUTH 5 H.SCHADT,P.COUTTET,J.BLANK,I.GALUBA,J.TRAPPE,J.VOSHOL, JRNL AUTH 6 N.OSTERMANN,C.ZOU,J.BERGHAUSEN,A.DEL RIO ESPINOLA,W.JAHNKE, JRNL AUTH 7 P.FURET JRNL TITL DISCOVERY OF ROBLITINIB (FGF401) AS A REVERSIBLE-COVALENT JRNL TITL 2 INHIBITOR OF THE KINASE ACTIVITY OF FIBROBLAST GROWTH FACTOR JRNL TITL 3 RECEPTOR 4. JRNL REF J.MED.CHEM. V. 63 12542 2020 JRNL REFN ISSN 0022-2623 JRNL PMID 32930584 JRNL DOI 10.1021/ACS.JMEDCHEM.0C01019 REMARK 2 REMARK 2 RESOLUTION. 2.13 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER 2.11.6 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.13 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 45.98 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.3 REMARK 3 NUMBER OF REFLECTIONS : 37437 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.198 REMARK 3 R VALUE (WORKING SET) : 0.196 REMARK 3 FREE R VALUE : 0.231 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.360 REMARK 3 FREE R VALUE TEST SET COUNT : 1634 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.010 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 19 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 2.13 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 2.19 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 95.86 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 2761 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.2310 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2639 REMARK 3 BIN R VALUE (WORKING SET) : 0.2270 REMARK 3 BIN FREE R VALUE : 0.3130 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.42 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 122 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.000 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4318 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 99 REMARK 3 SOLVENT ATOMS : 238 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 41.05 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 45.28 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 7.59450 REMARK 3 B22 (A**2) : -2.53280 REMARK 3 B33 (A**2) : -5.06170 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.270 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.217 REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.176 REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.208 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : 0.174 REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.943 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.923 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 4544 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 6173 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 1560 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : 101 ; 2.000 ; HARMONIC REMARK 3 GENERAL PLANES : 648 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 4544 ; 20.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 543 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 5265 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.010 REMARK 3 BOND ANGLES (DEGREES) : 1.03 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 3.06 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 17.08 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 6YI8 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 01-APR-20. REMARK 100 THE DEPOSITION ID IS D_1292107678. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 03-FEB-16 REMARK 200 TEMPERATURE (KELVIN) : 100.000 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SLS REMARK 200 BEAMLINE : X06SA REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.00001049042 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS EIGER X 16M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : XSCALE REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 37439 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.130 REMARK 200 RESOLUTION RANGE LOW (A) : 45.980 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.3 REMARK 200 DATA REDUNDANCY : 4.170 REMARK 200 R MERGE (I) : 0.04800 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 19.0100 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.13 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.23 REMARK 200 COMPLETENESS FOR SHELL (%) : 97.3 REMARK 200 DATA REDUNDANCY IN SHELL : 4.07 REMARK 200 R MERGE FOR SHELL (I) : 0.44500 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 3.890 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: 4TYG REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 48.46 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.39 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: MIXING 0.5 UL OF PROTEIN SOLUTION (13 REMARK 280 MG/ML IN 50 MM HEPES PH 8.0, 100 MM NACL, 3% GLYCEROL, 1 MM TCEP REMARK 280 AND 2 MM ROBLITINIB INCUBATED FOR 1H ON ICE) WITH 0.5 UL OF REMARK 280 RESERVOIR SOLUTION (13.5 % PEG 3350, 0.1 M (NH4)2SO4, 0.1 M NAAC REMARK 280 PH 4.25), VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 91.85350 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 26.55700 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 33.59900 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 26.55700 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 91.85350 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 33.59900 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ALA A 447 REMARK 465 GLY A 448 REMARK 465 LEU A 449 REMARK 465 VAL A 450 REMARK 465 SER A 451 REMARK 465 LEU A 452 REMARK 465 PRO A 574 REMARK 465 ASP A 575 REMARK 465 GLY A 576 REMARK 465 PRO A 577 REMARK 465 ARG A 578 REMARK 465 SER A 579 REMARK 465 SER A 580 REMARK 465 GLU A 581 REMARK 465 GLY A 582 REMARK 465 ARG A 635 REMARK 465 GLY A 636 REMARK 465 VAL A 637 REMARK 465 HIS A 638 REMARK 465 HIS A 639 REMARK 465 ILE A 640 REMARK 465 ASP A 641 REMARK 465 TYR A 642 REMARK 465 TYR A 643 REMARK 465 LYS A 644 REMARK 465 LYS A 645 REMARK 465 THR A 646 REMARK 465 SER A 647 REMARK 465 ASN A 648 REMARK 465 GLY A 649 REMARK 465 ALA B 447 REMARK 465 GLY B 448 REMARK 465 LEU B 449 REMARK 465 VAL B 450 REMARK 465 GLY B 569 REMARK 465 PRO B 570 REMARK 465 ASP B 571 REMARK 465 LEU B 572 REMARK 465 SER B 573 REMARK 465 PRO B 574 REMARK 465 ASP B 575 REMARK 465 GLY B 576 REMARK 465 PRO B 577 REMARK 465 ARG B 578 REMARK 465 SER B 579 REMARK 465 SER B 580 REMARK 465 GLU B 581 REMARK 465 GLY B 582 REMARK 465 LEU B 633 REMARK 465 ALA B 634 REMARK 465 ARG B 635 REMARK 465 GLY B 636 REMARK 465 VAL B 637 REMARK 465 HIS B 638 REMARK 465 HIS B 639 REMARK 465 ILE B 640 REMARK 465 ASP B 641 REMARK 465 TYR B 642 REMARK 465 TYR B 643 REMARK 465 LYS B 644 REMARK 465 LYS B 645 REMARK 465 THR B 646 REMARK 465 SER B 647 REMARK 465 ASN B 648 REMARK 465 GLY B 649 REMARK 465 ARG B 650 REMARK 465 GLU B 753 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LEU A 572 -51.80 -124.90 REMARK 500 ARG A 611 -18.38 79.66 REMARK 500 ALA B 553 76.67 -115.17 REMARK 500 LEU B 584 68.16 -110.57 REMARK 500 ARG B 611 -36.01 79.31 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue FGF A 801 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue SO4 A 802 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue SO4 A 803 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue SO4 A 804 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue SO4 B 802 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue SO4 B 803 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC7 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for Di-peptide FGF B 801 and CYS B REMARK 800 552 DBREF 6YI8 A 447 753 UNP P22455 FGFR4_HUMAN 407 713 DBREF 6YI8 B 447 753 UNP P22455 FGFR4_HUMAN 407 713 SEQRES 1 A 307 ALA GLY LEU VAL SER LEU ASP LEU PRO LEU ASP PRO LEU SEQRES 2 A 307 TRP GLU PHE PRO ARG ASP ARG LEU VAL LEU GLY LYS PRO SEQRES 3 A 307 LEU GLY GLU GLY CYS PHE GLY GLN VAL VAL ARG ALA GLU SEQRES 4 A 307 ALA PHE GLY MET ASP PRO ALA ARG PRO ASP GLN ALA SER SEQRES 5 A 307 THR VAL ALA VAL LYS MET LEU LYS ASP ASN ALA SER ASP SEQRES 6 A 307 LYS ASP LEU ALA ASP LEU VAL SER GLU MET GLU VAL MET SEQRES 7 A 307 LYS LEU ILE GLY ARG HIS LYS ASN ILE ILE ASN LEU LEU SEQRES 8 A 307 GLY VAL CYS THR GLN GLU GLY PRO LEU TYR VAL ILE VAL SEQRES 9 A 307 GLU CYS ALA ALA LYS GLY ASN LEU ARG GLU PHE LEU ARG SEQRES 10 A 307 ALA ARG ARG PRO PRO GLY PRO ASP LEU SER PRO ASP GLY SEQRES 11 A 307 PRO ARG SER SER GLU GLY PRO LEU SER PHE PRO VAL LEU SEQRES 12 A 307 VAL SER CYS ALA TYR GLN VAL ALA ARG GLY MET GLN TYR SEQRES 13 A 307 LEU GLU SER ARG LYS CYS ILE HIS ARG ASP LEU ALA ALA SEQRES 14 A 307 ARG ASN VAL LEU VAL THR GLU ASP ASN VAL MET LYS ILE SEQRES 15 A 307 ALA ASP PHE GLY LEU ALA ARG GLY VAL HIS HIS ILE ASP SEQRES 16 A 307 TYR TYR LYS LYS THR SER ASN GLY ARG LEU PRO VAL LYS SEQRES 17 A 307 TRP MET ALA PRO GLU ALA LEU PHE ASP ARG VAL TYR THR SEQRES 18 A 307 HIS GLN SER ASP VAL TRP SER PHE GLY ILE LEU LEU TRP SEQRES 19 A 307 GLU ILE PHE THR LEU GLY GLY SER PRO TYR PRO GLY ILE SEQRES 20 A 307 PRO VAL GLU GLU LEU PHE SER LEU LEU ARG GLU GLY HIS SEQRES 21 A 307 ARG MET ASP ARG PRO PRO HIS CYS PRO PRO GLU LEU TYR SEQRES 22 A 307 GLY LEU MET ARG GLU CYS TRP HIS ALA ALA PRO SER GLN SEQRES 23 A 307 ARG PRO THR PHE LYS GLN LEU VAL GLU ALA LEU ASP LYS SEQRES 24 A 307 VAL LEU LEU ALA VAL SER GLU GLU SEQRES 1 B 307 ALA GLY LEU VAL SER LEU ASP LEU PRO LEU ASP PRO LEU SEQRES 2 B 307 TRP GLU PHE PRO ARG ASP ARG LEU VAL LEU GLY LYS PRO SEQRES 3 B 307 LEU GLY GLU GLY CYS PHE GLY GLN VAL VAL ARG ALA GLU SEQRES 4 B 307 ALA PHE GLY MET ASP PRO ALA ARG PRO ASP GLN ALA SER SEQRES 5 B 307 THR VAL ALA VAL LYS MET LEU LYS ASP ASN ALA SER ASP SEQRES 6 B 307 LYS ASP LEU ALA ASP LEU VAL SER GLU MET GLU VAL MET SEQRES 7 B 307 LYS LEU ILE GLY ARG HIS LYS ASN ILE ILE ASN LEU LEU SEQRES 8 B 307 GLY VAL CYS THR GLN GLU GLY PRO LEU TYR VAL ILE VAL SEQRES 9 B 307 GLU CYS ALA ALA LYS GLY ASN LEU ARG GLU PHE LEU ARG SEQRES 10 B 307 ALA ARG ARG PRO PRO GLY PRO ASP LEU SER PRO ASP GLY SEQRES 11 B 307 PRO ARG SER SER GLU GLY PRO LEU SER PHE PRO VAL LEU SEQRES 12 B 307 VAL SER CYS ALA TYR GLN VAL ALA ARG GLY MET GLN TYR SEQRES 13 B 307 LEU GLU SER ARG LYS CYS ILE HIS ARG ASP LEU ALA ALA SEQRES 14 B 307 ARG ASN VAL LEU VAL THR GLU ASP ASN VAL MET LYS ILE SEQRES 15 B 307 ALA ASP PHE GLY LEU ALA ARG GLY VAL HIS HIS ILE ASP SEQRES 16 B 307 TYR TYR LYS LYS THR SER ASN GLY ARG LEU PRO VAL LYS SEQRES 17 B 307 TRP MET ALA PRO GLU ALA LEU PHE ASP ARG VAL TYR THR SEQRES 18 B 307 HIS GLN SER ASP VAL TRP SER PHE GLY ILE LEU LEU TRP SEQRES 19 B 307 GLU ILE PHE THR LEU GLY GLY SER PRO TYR PRO GLY ILE SEQRES 20 B 307 PRO VAL GLU GLU LEU PHE SER LEU LEU ARG GLU GLY HIS SEQRES 21 B 307 ARG MET ASP ARG PRO PRO HIS CYS PRO PRO GLU LEU TYR SEQRES 22 B 307 GLY LEU MET ARG GLU CYS TRP HIS ALA ALA PRO SER GLN SEQRES 23 B 307 ARG PRO THR PHE LYS GLN LEU VAL GLU ALA LEU ASP LYS SEQRES 24 B 307 VAL LEU LEU ALA VAL SER GLU GLU HET FGF A 801 37 HET SO4 A 802 5 HET SO4 A 803 5 HET SO4 A 804 5 HET FGF B 801 37 HET SO4 B 802 5 HET SO4 B 803 5 HETNAM FGF N-[5-CYANO-4-(2-METHOXYETHYLAMINO)PYRIDIN-2-YL]-7- HETNAM 2 FGF METHANOYL-6-[(4-METHYL-2-OXIDANYLIDENE-PIPERAZIN-1- HETNAM 3 FGF YL)METHYL]-3,4-DIHYDRO-2H-1,8-NAPHTHYRIDINE-1- HETNAM 4 FGF CARBOXAMIDE HETNAM SO4 SULFATE ION HETSYN FGF ROBLITINIB; FGF-401 FORMUL 3 FGF 2(C25 H30 N8 O4) FORMUL 4 SO4 5(O4 S 2-) FORMUL 10 HOH *238(H2 O) HELIX 1 AA1 PRO A 463 ASP A 465 5 3 HELIX 2 AA2 SER A 510 GLY A 528 1 19 HELIX 3 AA3 LEU A 558 ALA A 564 1 7 HELIX 4 AA4 SER A 585 ARG A 606 1 22 HELIX 5 AA5 ALA A 614 ARG A 616 5 3 HELIX 6 AA6 PRO A 652 MET A 656 5 5 HELIX 7 AA7 ALA A 657 ARG A 664 1 8 HELIX 8 AA8 THR A 667 THR A 684 1 18 HELIX 9 AA9 PRO A 694 GLU A 704 1 11 HELIX 10 AB1 PRO A 715 TRP A 726 1 12 HELIX 11 AB2 ALA A 729 ARG A 733 5 5 HELIX 12 AB3 THR A 735 SER A 751 1 17 HELIX 13 AB4 PRO B 463 ASP B 465 5 3 HELIX 14 AB5 SER B 510 GLY B 528 1 19 HELIX 15 AB6 ASN B 557 ARG B 566 1 10 HELIX 16 AB7 SER B 585 ARG B 606 1 22 HELIX 17 AB8 ALA B 614 ARG B 616 5 3 HELIX 18 AB9 PRO B 652 MET B 656 5 5 HELIX 19 AC1 ALA B 657 ARG B 664 1 8 HELIX 20 AC2 THR B 667 THR B 684 1 18 HELIX 21 AC3 PRO B 694 GLU B 704 1 11 HELIX 22 AC4 PRO B 715 TRP B 726 1 12 HELIX 23 AC5 ALA B 729 ARG B 733 5 5 HELIX 24 AC6 THR B 735 SER B 751 1 17 SHEET 1 AA1 5 LEU A 467 GLU A 475 0 SHEET 2 AA1 5 GLY A 479 PHE A 487 -1 O ARG A 483 N GLY A 470 SHEET 3 AA1 5 ALA A 497 LEU A 505 -1 O VAL A 500 N ALA A 484 SHEET 4 AA1 5 TYR A 547 GLU A 551 -1 O VAL A 548 N LYS A 503 SHEET 5 AA1 5 LEU A 536 CYS A 540 -1 N LEU A 537 O ILE A 549 SHEET 1 AA2 3 GLY A 556 ASN A 557 0 SHEET 2 AA2 3 VAL A 618 VAL A 620 -1 O VAL A 620 N GLY A 556 SHEET 3 AA2 3 MET A 626 ILE A 628 -1 O LYS A 627 N LEU A 619 SHEET 1 AA3 5 LEU B 467 GLU B 475 0 SHEET 2 AA3 5 GLY B 479 PHE B 487 -1 O GLU B 485 N VAL B 468 SHEET 3 AA3 5 ALA B 497 LEU B 505 -1 O MET B 504 N GLN B 480 SHEET 4 AA3 5 TYR B 547 GLU B 551 -1 O VAL B 548 N LYS B 503 SHEET 5 AA3 5 LEU B 536 CYS B 540 -1 N LEU B 537 O ILE B 549 SHEET 1 AA4 2 VAL B 618 VAL B 620 0 SHEET 2 AA4 2 MET B 626 ILE B 628 -1 O LYS B 627 N LEU B 619 LINK SG CYS A 552 CAL FGF A 801 1555 1555 1.93 LINK SG CYS B 552 CAL FGF B 801 1555 1555 1.92 SITE 1 AC1 17 LEU A 473 GLY A 474 ARG A 483 THR A 499 SITE 2 AC1 17 VAL A 500 ALA A 501 LYS A 503 ILE A 534 SITE 3 AC1 17 GLU A 551 CYS A 552 ALA A 553 ALA A 554 SITE 4 AC1 17 GLY A 556 LEU A 619 SO4 A 804 HOH A 931 SITE 5 AC1 17 HOH A 955 SITE 1 AC2 4 ARG A 563 ARG A 566 GLY A 687 SER A 688 SITE 1 AC3 3 ARG A 710 PRO A 712 HIS A 713 SITE 1 AC4 2 ARG A 483 FGF A 801 SITE 1 AC5 3 LYS B 555 ARG B 565 ASN B 624 SITE 1 AC6 3 ARG B 483 FGF B 801 HOH B 929 SITE 1 AC7 20 LEU B 473 GLY B 474 ARG B 483 THR B 499 SITE 2 AC7 20 VAL B 500 ALA B 501 LYS B 503 ILE B 534 SITE 3 AC7 20 VAL B 550 GLU B 551 ALA B 553 ALA B 554 SITE 4 AC7 20 GLY B 556 LEU B 619 SO4 B 803 HOH B 922 SITE 5 AC7 20 HOH B 925 HOH B 961 HOH B 972 HOH B 973 CRYST1 183.707 67.198 53.114 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.005443 0.000000 0.000000 0.00000 SCALE2 0.000000 0.014881 0.000000 0.00000 SCALE3 0.000000 0.000000 0.018827 0.00000